Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer (vol 76, pg 925, 2015)

被引：0

作者：

Bendell, Johanna C. ^{[1
]}

Rosen, Lee S. ^{[2
]}

Mayer, Robert J. ^{[3
]}

Goldman, Jonathan W. ^{[2
]}

Infante, Jeffrey R. ^{[1
]}

Benedetti, Fabio ^{[4
]}

Lin, Donghu ^{[5
]}

Mizuguchi, Hirokazu ^{[4
]}

Zergebel, Christopher ^{[4
]}

Patel, Manish R. ^{[6
]}

机构：

[1] PLLC, Sarah Cannon Res Inst, Tennessee Oncol, 250 25th Ave North,Suite 200, Nashville, TN 37203 USA

[2] Univ Calif, 2020 Santa Monica Blvd,Suite 600, Santa Monica, CA 90404 USA

[3] Dana Farber Canc Inst, 450 Brookline Ave,Dana 1602, Boston, MA 02215 USA

[4] Taiho Oncol Inc, 202 Carnegie Ctr,Suite 100, Princeton, NJ 08540 USA

[5] Taiho Pharmaceut Beijing Co Ltd, 9F-9A3,Hanwei Plaza,7th,Guanghua Rd, Beijing 100004, Peoples R China

[6] Sarah Cannon Res Inst, Florida Canc Specialists, 600 N Cattlemen Rd,Suite 200, Sarasota, FL 34232 USA

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2016年 / 77卷 / 02期

关键词：

D O I：

10.1007/s00280-015-2890-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：439 / 439

页数：1

共 50 条

[41] Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results
Kagawa, Y.
Satake, H.
Kato, T.
Oba, K.
Yasui, H.
Nakamura, M.
Watanabe, T.
Hirata, K.
Muro, K.
Komatsu, Y.
Yoshino, T.
Yamazaki, K.
Mishima, H.
Kotaka, M.
Tsuji, A.
Kakeji, Y.
Oki, E.
Nagata, N.
Junichi, S.
ANNALS OF ONCOLOGY, 2018, 29
[42] TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?
Eng, Cathy
LANCET ONCOLOGY, 2020, 21 (03): : 326 - 327
[43] Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102
Hamauchi, Satoshi
Yamazaki, Kentaro
Masuishi, Toshiki
Kito, Yosuke
Komori, Azusa
Tsushima, Takahiro
Narita, Yukiya
Todaka, Akiko
Ishihara, Makoto
Yokota, Tomoya
Tanaka, Tsutomu
Machida, Nozomu
Kadowaki, Shigenori
Fukutomi, Akira
Ura, Takashi
Onozawa, Yusuke
Ando, Masashi
Tajika, Masahiro
Muro, Kei
Yasui, Hirofumi
Mori, Keita
Taniguchi, Hiroya
CLINICAL COLORECTAL CANCER, 2017, 16 (01) : 51 - 57
[44] TAS-102 plus bevacizumah with metastatic colorectal cancer in salvage line
Osawa, Hiroshi
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 42 : S23 - S23
[45] Review on TAS-102 development and its use for metastatic colorectal cancer
Mota, Jose Mauricio
Fonseca, Leonardo G.
Braghiroli, Maria Ignez
Hoff, Paulo M.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 104 : 91 - 97
[46] TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
Liu, Cheng-Jiang
Hu, Ting
Shao, Ping
Chu, Wu-Yang
Cao, Yu
Zhang, Feng
GASTROENTEROLOGY RESEARCH AND PRACTICE, 2021, 2021
[47] Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States
Cho, Sang Kyu
Hay, Joel W.
Barzi, Afsaneh
CLINICAL COLORECTAL CANCER, 2018, 17 (04) : E751 - E761
[48] Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer
Kotani, D.
Kuboki, Y.
Yasuda, K.
Nakamura, Y.
Kawazoe, A.
Bando, H.
Taniguchi, H.
Shitara, K.
Yoshino, T.
ANNALS OF ONCOLOGY, 2018, 29 : 34 - 34
[49] A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Chen, Xiaochen
Qiu, Huafeng
Chen, Yunwang
Wang, Mingxing
Zhu, Pengfei
Pan, Shuangyue
Deng, Yaya
Yang, Liu
Chen, Zheling
FRONTIERS IN ONCOLOGY, 2021, 11
[50] A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer
Sonbol, Mohamad Bassam
Benkhadra, Raed
Wang, Zhen
Firwana, Belal
Walden, Daniel J.
Mody, Kabir
Hubbard, Joleen M.
Murad, M. Hassan
Ahn, Daniel H.
Bekaii-Saab, Tanios
ONCOLOGIST, 2019, 24 (09): : 1174 - 1179

← 1 2 3 4 5 →